YangHY 6x7Associate Research Fellow


Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Telephone: +886-2-27871308

 

 

EDUCATION AND POSITIONS HELD:

  • Ph.D., Graduate Institute of Epidemiology, School of Public Health, National Taiwan University, Taipei, Taiwan (2006)
  • Postdoctoral Fellow, Genomics Research Center, Academia Sinica, Taipei, Taiwan (2006- 2011)
  • Associate Professor, Graduate Institute of Clinical Medicine, China Medical University, Taichung, Taiwan (2011 - 2013)
  • Associate Research Fellow, Molecular and Genomic Epidemiology Center (MaGEC), China Medical University Hospital, Taichung, Taiwan (2011 - 2013)
  • Associate Research Fellow, Genomics Research Center, Academia Sinica, Taipei, Taiwan (2012 - present)
  • Adjunct Associate Professor, Graduate Institute of Clinical Medicine, National Yang-Ming University (2014 – present)

HONORS:

  • Prof. K-P Chen Award for the Best Public Health Paper, Taiwan Public Health Association (2004)
  • Honorary Member, Phi Tau Phi Scholastic Honor Society (2006)
  • Distinguished Postdoctoral Scholar of Academia Sinica (2007-2008)
  • The 20th Wang Ming-Ning Award (2010; as a member of the REVEAL-HBV study group led by Prof. Chien-Jen Chen)
  • Ta-You Wu Memorial Award, National Science Council, Taiwan (2013)
  • The 2013 Award for Outstanding Contributions in Science and Technology, Executive Yuan (2013; co-awardee: Prof. Chien-Jen Chen and Dr. Mei-Hsuan Lee)

RESEARCH INTERESTS:

  • Hepatitis Epidemiology: Delineating incidence and determinants of milestone transitions and disease progression in the natural history of chronic hepatitis B and C using longitudinal follow-up study.
  • Translational Epidemiology: Development and validation of risk prediction instruments which integrated multiple non-invasive clinical parameters for the prediction of marker transition and adverse sequelae of chronic hepatitis B and C.
  • Immunoepidemiology of Viral Hepatitis: Investigating roles of immunological factors of host on important outcomes of viral hepatitis using high-throughput molecular and genomic techniques including genome-wide association study, next generation sequencing, and multiplex protein assay, and glycan array.
  • Immunoprevention of Major Cancers: Exploring useful genomic, proteomic, and glycomic pre-diagnostic biosignatures for predicting major cancers in order to develop novel tactics in cancer early diagnosis and cancer preventive vaccines.

SELECTED PUBLICATIONS:

  • Pan WC, Yang HI*, 2017, “Response to RE: Fine Particle Pollution, Alanine Transaminase, and Liver Cancer: A Taiwanese Prospective Cohort Study (REVEAL-HBV)”, JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 109(1), djw185. (SCI)
  • Yang HI, Tseng TC, Liu J, Lee MH, Liu CJ, Su TH, Batrla-Utermann R, Chan HL, Kao JH, Chen CJ, 2016, “Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of HBV DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 14(3), 461-468. (SCI)
  • Hoang JK, Yang HI*, Le A, Nguyen NH, Lin D, Vu VD, Chaung K, Nguyen V, Trinh HN, Li J, Zhang JQ, Chen CJ, Nguyen MH*, 2016, “Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis.”, Medicine, 95(31), e4433. (SCI)
  • Chen CJ, Yang HI, Lee MH, Liu J, Hu HH, 2016, “Natural history of HBV infection in the community”, editor(s): Liaw YF, Zoulim F, Hepatitis B Virus in Human Diseases, pp. 249-276, Switzerland: Springer International Publishing Switzerland.
  • Chen YC*, Hsiao CJ, Jung CC, Hu HH, Chen JH, Lee WC, Chiou JM, Chen TF, Sun Y, Wen LL, Yip PK, Chu YM, Chen CJ*, Yang HI*, 2016, “Performance Metrics for Selecting Single Nucleotide Polymorphisms in Late-onset Alzheimer's Disease.”, Scientific Reports, 6, 36155. (SCI)
  • Poh Z, Shen L, Yang HI, Seto WK, Wong VW, Lin CY, Goh BG, Chang PJ, Chan HL, Yuen MF, Chen CJ, Tan CK, 2016, “Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B.”, Gut, 65(5), 887-888. (SCI)
  • Lin D, Yang HI*, Nguyen N, Hoang J, Kim Y, Vu V, Le A, Chaung K, Nguyen V, Trinh H, Li J, Zhang J, Hsing A, Chen CJ, Nguyen MH*, 2016, “Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients.”, Alimentary pharmacology & therapeutics, 44(8), 846-855. (SCI)
  • Liu J, Yang HI, Lee MH, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, You SL, Chen CJ, 2016, “Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression.”, HEPATOLOGY, 64(2), 381-389. (SCI)
  • Hu HH, Liu J, Lin YL, Luo WS, Chu YJ, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, You SL, Yang HI*, Chen CJ, 2016, “The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.”, Gut, 65, 1514-1521. (SCI)
  • Pan WC, Wu CD, Chen MJ, Huang YT, Chen CJ, Su HJ, Yang HI*, 2015, “Fine Particle Pollution, Alanine Transaminase, and Liver Cancer: A Taiwanese Prospective Cohort Study (REVEAL-HBV)”, JNCI-Journal of the National Cancer Institute, 108(3). pii: djv341. doi: 10.1093/jnci/djv341.. (SCI)
  • Huang HC, Yang HI, Chou HC, Chen CY, Hsieh WS, Tsou KI, Tsao PN, 2015, “Preeclampsia and Retinopathy of Prematurity in Very Low-Birth-Weight Infants: A Population-based Study”, PLoS One, 10(11), e0143248 (co-1st author). (SCI)
  • Liu J, Yang HI, Lee MH, Hsu WL, Chen HC, Chen CJ, 2015, “Epidemiology of virus infection and human cancer”, editor(s): Shurin MR, Thanavala Y, Ismail N, Infection and Cancer: Bi-Directorial Interactions, pp. 23-48, Switzerland: Springer International Publishing Switzerland.
  • Huang YT, Yang HI, Liu J, Lee MH, Freeman JR, Chen CJ, 2015, “Mediation Analysis of Hepatitis B and C in Relation to Hepatocellular Carcinoma Risk.”, EPIDEMIOLOGY, 27(1), 14-20. (SCI, SSCI) (IF: 6.075; SCI ranking: 5.2%; SSCI ranking: 2.6%)
  • Hwai-I Yang*, Jessica Liu, Mei-Hsuan Lee, Hui-Han Hu, Chia-Ling Chang, Chien-Jen Chen, 2015, “Natural history of occult hepatitis B virus infection”, editor(s): Jean-Pierre Allain, Yongshui Fu, Chengyao Li, Giovanni Raimondo, Occult Hepatitis B Infection, pp. 1-21, Beijing, China: Science Press.
  • Liu J, Tseng TC, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, Wang LY, You SL, Chen PJ, Chen CJ, Kao JH, 2015, “Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System.”, The Journal of infectious diseases, 211(10), 1566-1573. (SCI)
  • Lee MH, Lu SN, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L'italien G, Chen CJ, 2014, “Development and Validation of a Clinical Scoring System for Predicting Risk of HCC in Asymptomatic Individuals Seropositive for Anti-HCV Antibodies.”, PloS one, 9(5), e94760. (SCI)
  • Liu J, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, Wang LY, You SL, Hsiao CK, Chen CJ, 2014, “Distinct Seromarkers Predict Different Milestones of Chronic Hepatitis B Progression.”, HEPATOLOGY, 60(1), 77-86. (SCI)
  • Chen CJ, Hsu WL, Yang HI, Lee MH, Chen HC, Chien YC, You SL, 2014, “Epidemiology of virus infection and human cancer.”, Recent results in cancer research, 193, 11-32.
  • Chen CL, Yang WS, Yang HI, Chen CF, You SL, Wang LY, Lu SN, Liu CJ, Kao JH, Chen PJ, Chen DS, Chen CJ, 2014, “Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus infected carriers: a prospective study in Taiwan.”, CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 23(8), 1659-1671. (SCI)
  • Yang HI*, Lee MH, Liu J, Chen CJ, 2014, “Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia.”, WORLD JOURNAL OF GASTROENTEROLOGY, 20(20), 6244-6251. (SCI)
  • Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla-Utermann R, Wang LY, You SL, Hsiao CK, Chen PJ, Chen CJ, 2014, “Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma.”, Gut, 63(10), 1648-1657. (SCI)
  • Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao CK, Yang HI, Chen CJ, 2013, “A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection.”, JOURNAL OF HEPATOLOGY, 58(5), 853-860. (SCI)
  • Wu HC, Wang Q, Yang HI, Tsai WY, Chen CJ, Santella RM, 2013, “Global DNA methylation in a population with aflatoxin B1 exposure.”, Epigenetics, 8(9), 962-969. (SCI)
  • Cheng HR, Liu CJ, Tseng TC, Su TH, Yang HI, Chen CJ, Kao JH, 2013, “Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients.”, PLoS One, 8(1), e53008. (SCI)
  • Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, Lu SN, Liu J, Chen CJ, 2013, “Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients.”, PLoS One, 8(4), e61448. (SCI)
  • Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, You SL, Wang LY, Chen CJ, 2013, “Prediction models of long-term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles.”, HEPATOLOGY, 58(2), 546-554. (SCI)
  • Yen TA, Yang HI, Hsieh WS, Chou HC, Chen CY, Tsou KI, Tsao PN, 2013, “Preeclampsia and the Risk of Bronchopulmonary Dysplasia in VLBW Infants: A Population Based Study.”, PloS one, 8(9), e75168. (SCI)
  • Lin PH, Lin CC, Yang HI, Li LY, Bai LY, Chiu CF, Liao YM, Lin CY, Hsieh CY, Lin CY, Ho CM, Yang SF, Peng CT, Tsai FJ, Yeh SP, 2013, “Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3.”, LEUKEMIA RESEARCH, 37(3), 287-292. (SCI)
  • Loomba R*, Yang HI*, Su J, Brenner D, Barrett-Connor E, Iloeje U, Chen CJ, 2013, “Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study.”, AMERICAN JOURNAL OF EPIDEMIOLOGY, 177(4), 333-342. (SCI)
  • Loomba R*, Liu J, Yang HI*, Lee MH, Lu SN, Wang LY, Iloeje UH, You SL, Brenner D, Chen CJ, 2013, “Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma.”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 11(12), 1636-1645.e1-3. (SCI)
  • Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ, 2012, “Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study.”, JOURNAL OF INFECTIOUS DISEASES, 206(4), 469-477. (SCI)
  • Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC, 2012, “Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan.”, PLoS One, 7(4), e34779. (SCI)
  • Wu HC, Wang Q, Yang HI, Tsai WY, Chen CJ, Santella RM, 2012, “Global DNA methylation levels in white blood cells as a biomarker for hepatocellular carcinoma risk: a nested case-control study.”, CARCINOGENESIS, 33(7), 1340-1345. (SCI)
  • Yang HI*, Hung HL, Lee MH, Liu J, Jen CL, Su J, Wang LY, Lu SN, You SL, Iloeje UH, Chen CJ, 2012, “Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients with chronic hepatitis B.”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 10(5), 527-534. (SCI)
  • Huang HC, Yang HI, Chang YH, Chang RJ, Chen MH, Chen CY, Chou HC, Hsieh WS, Tsao PN, 2012, “Model to predict hyperbilirubinemia in healthy term and near-term newborns with exclusive breast feeding.”, Pediatrics and Neonatology, 53(6), 354-358. (SCI)
  • Iloeje UH, Yang HI*, Chen CJ, 2012, “Natural history of chronic hepatitis B: what exactly has REVEAL revealed?”, LIVER INTERNATIONAL, 32(9), 1333-1341. (SCI)
  • Chou HC, Chen MH, Yang HI, Su YN, Hsieh WS, Chen CY, Chen HL, Chang MH, Tsao PN, 2011, “211 G to a variation of UDP-glucuronosyl transferase 1A1 gene and neonatal breastfeeding jaundice.”, PEDIATRIC RESEARCH, 69(2), 170-174. (SCI)
  • Wei SC, Ni YH, Yang HI, Su YN, Chang MC, Chang YT, Shieh MJ, Wang CY, Wong JM, 2011, “A hospital-based study of clinical and genetic features of Crohn's disease.”, JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 110(9), 600-606. (SCI)
  • Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, Su J, Hsiao CK, Wang LY, You SL, Lu SN, Chen CJ, 2011, “Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.”, GASTROENTEROLOGY, 141(4), 1240-1248.e2. (SCI)
  • Lee MH, Yang HI, Jen CL, Lu SN, Yeh SH, Liu CJ, You SL, Sun CA, Wang LY, Chen WJ, Chen CJ, 2011, “Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991-2.”, GUT, 60(5), 688-694. (SCI)
  • Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, Iloeje UH, Chen CJ, 2011, “Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C.”, JOURNAL OF CLINICAL ONCOLOGY, 29(27), 3643-3650. (SCI)
  • Chen CJ, Yang HI, 2011, “Natural history of chronic hepatitis B REVEALed.”, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 26(4), 628-638. (SCI)
  • Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, Chen CJ, Wong VW, Seto WK, 2011, “Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.”, LANCET ONCOLOGY, 12(6), 568-574. (SCI)
  • Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J, Sun CA, Liaw YF, Chen CJ, 2010, “Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.”, GASTROENTEROLOGY, 138(5), 1747-1754. (SCI)
  • Wang CH, Chen CJ, Lee MH, Yang HI, Hsiao CK, 2010, “Chronic hepatitis B infection and risk of atherosclerosis-related mortality: A 17-year follow-up study based on 22,472 residents in Taiwan.”, ATHEROSCLEROSIS, 211(2), 624-629. (SCI)
  • Lee MH, Yang HI, Wang CH, Jen CL, Yeh SH, Liu CJ, You SL, Chen WJ, Chen CJ, 2010, “Hepatitis C virus infection and increased risk of cerebrovascular disease.”, STROKE, 41(12), 2894-900. (SCI)
  • Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, You SL, Wang LY, Chen WJ, Chen CJ, 2010, “Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study.”, JOURNAL OF CLINICAL ONCOLOGY, 28(30), 4587-4593. (SCI)
  • Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, You SL, Iloeje UH, Chen CJ, 2010, “Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.”, GASTROENTEROLOGY, 139(2), 474-482. (SCI)
  • Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, Chen CJ, 2010, “Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.”, JOURNAL OF CLINICAL ONCOLOGY, 28(14), 2437-2444. (SCI)
  • Loomba R, Yang HI, Su J, Brenner D, Iloeje U, Chen CJ, 2010, “Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men.”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 8(10), 891-898.e1-2. (SCI)
  • Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Lu SN, Chen CJ, 2010, “Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study.”, LIVER INTERNATIONAL, 30(3), 423-429. (SCI)
  • Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, Santella RM, 2009, “Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan.”, CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 18(3), 846-853. (SCI)
  • Chen CJ, Yang HI, Iloeje UH, 2009, “Hepatitis B virus DNA levels and outcomes in chronic hepatitis B.”, HEPATOLOGY, 49(5 Suppl), S72-S84. (SCI)
  • Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ, 2008, “Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.”, JNCI-Journal of the National Cancer Institute, 100(16), 1134-1143. (SCI)
  • Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ, 2008, “Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.”, GASTROENTEROLOGY, 135(1), 111-121. (SCI)
  • Wu HC, Wang Q, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, Santella RM, 2008, “Urinary 15-F2t-isoprostane, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan.”, CARCINOGENESIS, 29(5), 971-976. (SCI)
  • Chen CJ, Iloeje UH, Yang HI, 2007, “Long-term outcomes in hepatitis B: the REVEAL-HBV study.”, Clinics in Liver Disease, 11(4), 797-816. (SCI)
  • Wu HC, Wang Q, Wang LW, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, Santella RM, 2007, “Polycyclic aromatic hydrocarbon- and aflatoxin-albumin adducts, hepatitis B virus infection and hepatocellular carcinoma in Taiwan.”, CANCER LETTERS, 252(1), 104-114. (SCI)
  • Zhang YJ, Wu HC, Shen J, Ahsan H, Tsai WY, Yang HI, Wang LY, Chen SY, Chen CJ, Santella RM, 2007, “Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA.”, CLINICAL CANCER RESEARCH, 13(8), 2378-2384. (SCI)
  • Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Chen CJ, 2007, “Risk and predictors of mortality associated with chronic hepatitis B infection.”, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 5(8), 921-931. (SCI)
  • Wu HC, Wang Q, Wang LW, Yang HI, Ahsan H, Tsai WY, Wang LY, Chen SY, Chen CJ, Santella RM, 2007, “Urinary 8-oxodeoxyguanosine, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan.”, CARCINOGENESIS, 28(5), 995-999. (SCI)
  • Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, 2006, “Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.”, GASTROENTEROLOGY, 130(3), 678-686. (SCI)
  • Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, 2006, “Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.”, JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295(1), 65-73. (SCI)
  • You SL, Yang HI, Chen CJ, 2004, “Seropositivity of hepatitis B e antigen and hepatocellular carcinoma.”, ANNALS OF MEDICINE, 36(3), 215-224. (SCI)
  • Wang LY, You SL, Lu SN, Ho HC, Wu MH, Sun CA, Yang HI, Chien-Jen C, 2003, “Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan.”, CANCER CAUSES & CONTROL, 14(3), 241-250. (SCI)
  • Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ, 2002, “Hepatitis B e antigen and the risk of hepatocellular carcinoma.”, NEW ENGLAND JOURNAL OF MEDICINE, 347(3), 168-174. (SCI)
  • Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS, 2001, “Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men.”, NEW ENGLAND JOURNAL OF MEDICINE, 345(26), 1877-1882. (SCI)